Primary effusion lymphoma: Difference between revisions
No edit summary |
No edit summary |
||
Line 21: | Line 21: | ||
==Overview== | ==Overview== | ||
'''Primary effusion lymphoma''' (PEL) is a malignancy of B cells that is caused by [[Kaposi's sarcoma-associated herpesvirus]] (KSHV), also known as human herpesvirus 8 (HHV-8)<ref>Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332(18):1186-91.</ref>. In about 80% of cases, the lymphoma cells are also infected with [[Epstein Barr virus]] (EBV). PEL is unusual in that the majority of cases arise in body cavities, such as the pleural space or the pericardium; another name for PEL is "body cavity lymphoma"<ref>Staudt MR, Kanan Y, Jeong JH, Papin JF, Hines-Boykin R, Dittmer DP. The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res 2004;64(14):4790-9.</ref>. | '''Primary effusion lymphoma''' (PEL) is a malignancy of B cells that is caused by [[Kaposi's sarcoma-associated herpesvirus]] (KSHV), also known as human herpesvirus 8 (HHV-8)<ref>Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332(18):1186-91.</ref>. In about 80% of cases, the lymphoma cells are also infected with [[Epstein Barr virus]] (EBV). PEL is unusual in that the majority of cases arise in body cavities, such as the pleural space or the pericardium; another name for PEL is "body cavity lymphoma"<ref>Staudt MR, Kanan Y, Jeong JH, Papin JF, Hines-Boykin R, Dittmer DP. The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res 2004;64(14):4790-9.</ref>. | ||
==Historical Perspective== | |||
Primary effusion lymphoma was recognized as a unique type of lymphoma only after the discovery of KSHV in 1994. | |||
PEL most commonly arises in patients with underlying immunodeficiency, such as [[AIDS]]<ref>Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002;2(5):373-82.</ref>. It is generally resistant to cancer chemotherapy drugs that are active against other lymphomas, and carries a very poor prognosis<ref>Yarchoan R, Tosato G, Little RF. Therapy insight: AIDS-related malignancies - the influence of antiviral therapy on pathogenesis and management. Nature Clin Prac Oncology 2005;2(8):406-15.</ref>. | PEL most commonly arises in patients with underlying immunodeficiency, such as [[AIDS]]<ref>Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002;2(5):373-82.</ref>. It is generally resistant to cancer chemotherapy drugs that are active against other lymphomas, and carries a very poor prognosis<ref>Yarchoan R, Tosato G, Little RF. Therapy insight: AIDS-related malignancies - the influence of antiviral therapy on pathogenesis and management. Nature Clin Prac Oncology 2005;2(8):406-15.</ref>. |
Revision as of 12:26, 17 September 2012
Primary effusion lymphoma | |
ICD-O: | 9678/3 |
---|---|
DiseasesDB | 33904 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Body cavity lymphoma
Overview
Primary effusion lymphoma (PEL) is a malignancy of B cells that is caused by Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8)[1]. In about 80% of cases, the lymphoma cells are also infected with Epstein Barr virus (EBV). PEL is unusual in that the majority of cases arise in body cavities, such as the pleural space or the pericardium; another name for PEL is "body cavity lymphoma"[2].
Historical Perspective
Primary effusion lymphoma was recognized as a unique type of lymphoma only after the discovery of KSHV in 1994.
PEL most commonly arises in patients with underlying immunodeficiency, such as AIDS[3]. It is generally resistant to cancer chemotherapy drugs that are active against other lymphomas, and carries a very poor prognosis[4].
References
- ↑ Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332(18):1186-91.
- ↑ Staudt MR, Kanan Y, Jeong JH, Papin JF, Hines-Boykin R, Dittmer DP. The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res 2004;64(14):4790-9.
- ↑ Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002;2(5):373-82.
- ↑ Yarchoan R, Tosato G, Little RF. Therapy insight: AIDS-related malignancies - the influence of antiviral therapy on pathogenesis and management. Nature Clin Prac Oncology 2005;2(8):406-15.